<?xml version="1.0" encoding="UTF-8"?> <article key="pdf/9998299" mdate="2014-05-01 00:00:00"> <author>M. Hoxha and V. Capra and C. Buccellati and A. Sala and C. Cena and R. Fruttero and M. Bertinaria and G. E. Rovati</author> <title>A New Gateway for Rheumatoid Arthritis COXIBs with an Improved Cardiovascular Profile</title> <pages>212 - 215</pages> <year>2014</year> <volume>8</volume> <number>4</number> <journal>International Journal of Pharmacological and Pharmaceutical Sciences</journal> <ee>https://publications.waset.org/pdf/9998299</ee> <url>https://publications.waset.org/vol/88</url> <publisher>World Academy of Science, Engineering and Technology</publisher> <abstract>Today COXIBs are used in the treatment of arthritis and many other painful conditions in selected patients with high gastrointestinal risk and low cardiovascular (CV) risk. Previously, we have identified an unexpected mechanism of action of a traditional nonsteroidal antiinflammatory drug (NSAID) (diclofenac) and a specific inhibitor of cyclooxygenase2 (COXIB) (lumiracoxib) demonstrating that they possess weak competitive antagonism at the thromboxane receptor (TP). We hypothesize that modifying the structure of a known COXIB so that it becomes also a more potent TP antagonist will preserve the antiinflammatory and gastrointestinal safety typical of COXIBs and prevent the CV risk associated with long term therapy. </abstract> <index>Open Science Index 88, 2014</index> </article>